Axsome Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2017 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Axsome Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2017 to Q3 2024.
  • Axsome Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 323 %, a 113% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 323 +172 +113% Sep 30, 2024
Q2 2024 223 +68.6 +44.5% Jun 30, 2024
Q1 2024 166 -49.2 -22.9% Mar 31, 2024
Q4 2023 157 -59.2 -27.4% Dec 31, 2023
Q3 2023 151 -91.8 -37.8% Sep 30, 2023
Q2 2023 154 -282 -64.7% Jun 30, 2023
Q1 2023 215 +12.9 +6.39% Mar 31, 2023
Q4 2022 217 +89 +69.7% Dec 31, 2022
Q3 2022 243 +154 +173% Sep 30, 2022
Q2 2022 437 +369 +543% Jun 30, 2022
Q1 2022 202 +152 +307% Mar 31, 2022
Q4 2021 128 +88.4 +226% Dec 31, 2021
Q3 2021 89 +58.8 +195% Sep 30, 2021
Q2 2021 67.9 +36.1 +113% Jun 30, 2021
Q1 2021 49.7 +8.24 +19.9% Mar 31, 2021
Q4 2020 39.2 -20.9 -34.8% Dec 31, 2020
Q3 2020 30.2 -191 -86.3% Sep 30, 2020
Q2 2020 31.8 -169 -84.1% Jun 30, 2020
Q1 2020 41.4 -231 -84.8% Mar 31, 2020
Q4 2019 60.1 -221 -78.7% Dec 31, 2019
Q3 2019 221 +47.2 +27.2% Sep 30, 2019
Q2 2019 200 +78.7 +64.7% Jun 30, 2019
Q1 2019 273 +177 +184% Mar 31, 2019
Q4 2018 282 +202 +254% Dec 31, 2018
Q3 2018 174 +101 +138% Sep 30, 2018
Q2 2018 122 Jun 30, 2018
Q1 2018 96.2 Mar 31, 2018
Q4 2017 79.5 Dec 31, 2017
Q3 2017 72.8 Sep 30, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.